Anavex life sciences to present at the 41st annual j.p. morgan healthcare conference

New york, dec. 12, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced that it will present at the 41st annual j.p. morgan healthcare conference on thursday, january 12th 2023, at the westin st. francis in san francisco, ca. christopher u missling, phd, president & chief executive officer will present the company in a session scheduled 08:15 am - 08:55 am (pacific time).
AVXL Ratings Summary
AVXL Quant Ranking